Stock JNJ0 JOHNSON & JOHNSON
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Johnson & Johnson Deutsche Boerse AG

Equities

JNJ0

CA47817E1034

Market Closed - Deutsche Boerse AG
Other stock markets
 02:16:26 2024-05-28 EDT 		5-day change 1st Jan Change
12.9 EUR 0.00% Intraday chart for Johnson & Johnson -4.44% -5.84%
09:56pm Sector Update: Health Care Stocks Fall Late Afternoon MT
08:02pm Sector Update: Health Care Stocks Retreat Tuesday Afternoon MT

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • With an enterprise value anticipated at 3.92 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The company appears highly valued given the size of its balance sheet.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.84% 354B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.59% 727B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.66% 328B
B-
ABBVIE INC. Stock AbbVie Inc.
+0.24% 277B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.47% 243B
B+
NOVARTIS AG Stock Novartis AG
+7.35% 205B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-6.42% 203B
A+
AMGEN INC. Stock Amgen Inc.
+4.23% 164B
C+
PFIZER, INC. Stock Pfizer, Inc.
-1.70% 164B
C+
SANOFI Stock Sanofi
-1.31% 122B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. JNJ0 Stock
  5. Ratings Johnson & Johnson